| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Where rare
is common
Our genetic testing was developed by experienced geneticists, genetic counselors, laboratory scientists, and bioinformaticians. We focus on providing easy-to-understand answers, interpreted by those same experts, who have an intimate understanding of the testing and understand the impact the results have on patient care.
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
2,000+
new diagnoses made each year
30+
genetic experts developing testing and interpreting results
150+
quantitative and qualitative biochemical genetic assays performed
24/7
support from Mayo Clinic physicians and scientists
Expertise in analysis and interpretation
Genetic testing generates large amounts of complex data that require a high level of expertise to accurately assess and classify each abnormality detected. Our laboratory directors review thousands of tests each year and are actively involved in the field of genomics, helping create testing standards and shape practice guidelines.
Discovering the unknown
If further studies are necessary to clinically explore potential genetic causes for a patient’s phenotype or to characterize an identified abnormality, we offer an expansive test of exploratory genetic testing, including whole exome sequencing.
Access to Mayo Clinic expertise
Our laboratories operate as an interdisciplinary group of physicians, scientists, genetic counselors and laboratory professionals working in a state-of-the-art environment. This
team provides testing and result interpretation of the highest quality for the diagnosis and clinical care of patients.
Test in Focus
Cherisse Marcou, Ph.D., co-director of the Clinical Genomics Laboratory, and Marissa Ellingson, M.S., CGC, laboratory genetic counselor, discuss whole exome sequencing at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, deletion-insertions, and copy number variants in approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited disorders.
The latest
Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.
PACE/State of CA/State of FL - In this "Virtual Lecture," Kevin Halling, M.D., Ph.D., discusses the evolution of clinical laboratory molecular testing over the past 40 years and the types alterations that are detected by solid tumor comprehensive genomic profiling. He also summarizes the clinical utility of solid tumor comprehensive genomic profiling.
In this month's "Hot Topic," Paul Jannetto, Ph.D., identifies how to determine new vs. residual use of marijuana in a patient, and teaches how to calculate the carboxy-tetrahydrocannabinol (carboxy-THC) to creatinine ratio along with a decision ratio by demonstrating its clinical utility via case study.
PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” Eva Morava-Kozicz, M.D., Ph.D., discusses one of the most important post-translational modifications that happen in our bodies, glycosylation. More specifically, she focuses on congenital disorders of glycosylation.
PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” Victor Karpyak, M.D., Ph.D., discusses the burden of alcohol use disorders (AUD) on society compared to other neuropsychiatric disorders and reviews the progress of biomarker discovery.